Pacira | PCRX - Ebitda

Stock Price
23.09
Daily Change
-0.32 -1.37%
Monthly
12.63%
Yearly
-9.38%
Q1 Forecast
22.50

Pacira reported $49.36M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Astellas Pharma JPY 183.68B 31.98B Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Coherus Biosciences USD -44.34M 9.82M Mar/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
J&J USD 9.52B 389M Sep/2025
Ligand Pharmaceuticals USD 20.9M 61.44M Jun/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novo Nordisk DKK 37.3B 5.86B Dec/2025
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 49.36M 4.96M Sep/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Supernus Pharmaceuticals USD 48.5M 6.6M Dec/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Xeris Pharmaceuticals USD 17.42M 8.83M Sep/2025
Xoma USD 2.52M 7.98M Jun/2024
Zoetis USD 1.04B 87M Sep/2025